182 related articles for article (PubMed ID: 32193690)
1. Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1.
Gallitto M; Cheng He R; Inocencio JF; Wang H; Zhang Y; Deikus G; Wasserman I; Strahl M; Smith M; Sebra R; Yong RL
J Neurooncol; 2020 May; 147(3):557-566. PubMed ID: 32193690
[TBL] [Abstract][Full Text] [Related]
2. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
[TBL] [Abstract][Full Text] [Related]
4. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
5. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
Shinsato Y; Furukawa T; Yunoue S; Yonezawa H; Minami K; Nishizawa Y; Ikeda R; Kawahara K; Yamamoto M; Hirano H; Tokimura H; Arita K
Oncotarget; 2013 Dec; 4(12):2261-70. PubMed ID: 24259277
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Rahman MA; Gras Navarro A; Brekke J; Engelsen A; Bindesbøll C; Sarowar S; Bahador M; Bifulco E; Goplen D; Waha A; Lie SA; Gjertsen BT; Selheim F; Enger PØ; Simonsen A; Chekenya M
Br J Cancer; 2019 Oct; 121(7):545-555. PubMed ID: 31413318
[TBL] [Abstract][Full Text] [Related]
8. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
9. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
12. Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Massey SC; White H; Whitmire P; Doyle T; Johnston SK; Singleton KW; Jackson PR; Hawkins-Daarud A; Bendok BR; Porter AB; Vora S; Sarkaria JN; Hu LS; Mrugala MM; Swanson KR
PLoS One; 2020; 15(3):e0230492. PubMed ID: 32218600
[TBL] [Abstract][Full Text] [Related]
13. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
[TBL] [Abstract][Full Text] [Related]
14. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma Recurrence and the Role of O
Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
[TBL] [Abstract][Full Text] [Related]
17. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
Lee J; Kim E; Ryu SW; Choi C; Choi K
J Neurooncol; 2016 May; 128(1):29-34. PubMed ID: 26951556
[TBL] [Abstract][Full Text] [Related]
19. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
20. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
